The progress in research on neoadjuvant radiotherapy for rectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.01.01

Abstract

Abstract:

Neoadjuvant chemoradiation therapy (CRT) has been established as the standard care for local advanced rectal cancer. This approach has reduced the risk of local recurrence, led to reliable tumor down-staging and more sphincter preserving. For all these reasons, it has similar survival compared with adjuvant chemoradiation. Patients who achieve pathological complete response (pCR) after CRT have better long-term outcomes.

Key words: Rectal neoplasms, Therapy, Magnetic resonance imaging, Pathology

Fang Shi, Jinming Yu. The progress in research on neoadjuvant radiotherapy for rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 2-5.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.01.01

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I01/2

References 24

[1]	Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
[2]	Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 2006, 355(11):1114-1123.
[3]	Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in rectal cancer. N Engl J Med, 1997, 336(14): 980-987.
[4]	Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol, 2015, 133(16): 1797-1808.
[5]	Samdani T, Garcia-Aguilar J. Imaging in rectal cancer: magnetic resonance imaging vs. endorectal ultrasonography. Surg Oncol Clin N Am, 2014, 23(1): 59-77.
[6]	Brown G, Davies S, Williams GT,et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer, 2004, 91(1):23-29.
[7]	Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta analysis. Ann Surg Oncol, 2012, 19(7): 2212-2223.
[8]	Merkel S, Mansmann U, Siassi M, et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis, 2001, 16(5): 298-304.
[9]	Shin R, Jeong SY, Yoo HY, et al. Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer. Dis Colon Rectum, 2012, 55(12): 1220-1228.
[10]	MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology, 2007, 243(1): 132-139.
[11]	Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013, 24 (Suppl6): vi81-88.
[12]	Redel C, Sauer R. Neoedjuvant radiochemotherapy in rectal cancer；For which patient and tumor stages? Front Radiat Ther Oncol, 2004, 38(1): 13-23.
[13]	Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
[14]	Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 2010, 11(9): 835-844.
[15]	Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol, 2012; 30(15): 1770-1776.
[16]	Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and retum. Arch Pathol Lab Med, 2009, 133(10):1539-1551.
[17]	Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994, 73(11): 2680-2686.
[18]	Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1997, 12(1): 19-23.
[19]	Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advance rectal cancer. Histopathology, 2005, 47(2): 141-146.
[20]	Smith KD, Tan D, Das P, et al. Clinical significance of acelluar mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg, 2010, 251(2): 261-264.
[21]	Lim SB, Hong SM, Yu CS, et al. Prevalence and clinical significande of acelluar mucin in locally rectal cancer patients showing pathologic complete response to preoperative chemoradiotherapy. Am J Surg Pathol, 2013, 37(1): 47-52.
[22]	Shihab OC, Taylor F, Salerno G, et al. MRI predictive factors for long-term outcomes of low rectal tumours. Ann Surg Oncol, 2011, 18(12): 3278-3284.
[23]	Lambregts DM, Vandercaveye V, Barbaro B, et al. Diffusion-Weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol, 2011, 18(8): 2224-2231.
[24]	Hein PA, Kremser C, Judmaier W, et al. Diffusion-Weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol, 2003, 45(2): 214-222.

Please choose a citation manager

Content to export